JP2020105190A5 - - Google Patents

Download PDF

Info

Publication number
JP2020105190A5
JP2020105190A5 JP2020035656A JP2020035656A JP2020105190A5 JP 2020105190 A5 JP2020105190 A5 JP 2020105190A5 JP 2020035656 A JP2020035656 A JP 2020035656A JP 2020035656 A JP2020035656 A JP 2020035656A JP 2020105190 A5 JP2020105190 A5 JP 2020105190A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
disease
combination
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020035656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020105190A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020105190A publication Critical patent/JP2020105190A/ja
Publication of JP2020105190A5 publication Critical patent/JP2020105190A5/ja
Withdrawn legal-status Critical Current

Links

JP2020035656A 2012-10-16 2020-03-03 Ｐｋｍ２調節因子およびそれらの使用方法 Withdrawn JP2020105190A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261714659P 2012-10-16 2012-10-16
US61/714,659 2012-10-16
US201361875855P 2013-09-10 2013-09-10
US61/875,855 2013-09-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018186629A Division JP2019023209A (ja) 2012-10-16 2018-10-01 Ｐｋｍ２調節因子およびそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2020105190A JP2020105190A (ja) 2020-07-09
JP2020105190A5 true JP2020105190A5 (enExample) 2020-08-20

Family

ID=50488890

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2015537799A Active JP6243918B2 (ja) 2012-10-16 2013-10-16 Ｐｋｍ２調節因子およびそれらの使用方法
JP2017203963A Active JP6526767B2 (ja) 2012-10-16 2017-10-20 Ｐｋｍ２調節因子およびそれらの使用方法
JP2018186629A Withdrawn JP2019023209A (ja) 2012-10-16 2018-10-01 Ｐｋｍ２調節因子およびそれらの使用方法
JP2020035657A Withdrawn JP2020097631A (ja) 2012-10-16 2020-03-03 Ｐｋｍ２調節因子およびそれらの使用方法
JP2020035656A Withdrawn JP2020105190A (ja) 2012-10-16 2020-03-03 Ｐｋｍ２調節因子およびそれらの使用方法
JP2021120679A Active JP7128331B2 (ja) 2012-10-16 2021-07-21 Ｐｋｍ２調節因子およびそれらの使用方法
JP2021129580A Pending JP2021181467A (ja) 2012-10-16 2021-08-06 Ｐｋｍ２調節因子およびそれらの使用方法

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2015537799A Active JP6243918B2 (ja) 2012-10-16 2013-10-16 Ｐｋｍ２調節因子およびそれらの使用方法
JP2017203963A Active JP6526767B2 (ja) 2012-10-16 2017-10-20 Ｐｋｍ２調節因子およびそれらの使用方法
JP2018186629A Withdrawn JP2019023209A (ja) 2012-10-16 2018-10-01 Ｐｋｍ２調節因子およびそれらの使用方法
JP2020035657A Withdrawn JP2020097631A (ja) 2012-10-16 2020-03-03 Ｐｋｍ２調節因子およびそれらの使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021120679A Active JP7128331B2 (ja) 2012-10-16 2021-07-21 Ｐｋｍ２調節因子およびそれらの使用方法
JP2021129580A Pending JP2021181467A (ja) 2012-10-16 2021-08-06 Ｐｋｍ２調節因子およびそれらの使用方法

Country Status (6)

Country Link
US (5) US9394257B2 (enExample)
EP (1) EP2909181B1 (enExample)
JP (7) JP6243918B2 (enExample)
DK (1) DK2909181T3 (enExample)
ES (1) ES2644758T3 (enExample)
WO (1) WO2014062838A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2909181T3 (da) * 2012-10-16 2017-11-20 Tolero Pharmaceuticals Inc PKM2-modulatorer og fremgangsmåder til anvendelse deraf
KR102007135B1 (ko) 2017-03-20 2019-08-02 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
WO2019075367A1 (en) * 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3941463A1 (en) * 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
US20220162200A1 (en) * 2019-03-22 2022-05-26 Sumitomo Dainippon Pharma Oncology, Inc. Pkm2 modulators and methods for their use
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
JP2861087B2 (ja) * 1989-08-08 1999-02-24 三菱化学株式会社 Ｎ―アシル‐５‐ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
IT1255527B (it) * 1992-09-29 1995-11-09 Mini Ricerca Scient Tecnolog Pirazolcarbossammidi ad attivita' insetticida ed acaricida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
FI973974A7 (fi) 1995-04-20 1997-10-16 Pfizer Aryylisulfonyylihydroksaamihappojohdannaisia MMP- ja TNF-inhibiittorei na
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
DE19600097C1 (de) 1996-01-03 1997-07-31 Siemens Ag Verfahren und Vorrichtung zur Bestimmung einer Flüssigkeitshöhe mit Hilfe von Ultraschallimpulsen
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
CA2260058A1 (en) 1996-07-13 1998-01-22 Kathryn Jane Smith Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
HUP9903014A3 (en) 1996-07-18 2000-08-28 Pfizer Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
ES2224277T3 (es) 1997-01-06 2005-03-01 Pfizer Inc. Derivados de sulfonas ciclicas.
PT977733E (pt) 1997-02-03 2003-12-31 Pfizer Prod Inc Derivados de acido arilsulfonilamino-hidroxamico
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
ES2216293T3 (es) 1997-08-08 2004-10-16 Pfizer Products Inc. Derivados de acido ariloxiarilsulfonilamino-hidroxamico.
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999024440A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
TR200003514T2 (tr) 1998-05-29 2002-05-21 Sugen Inc. Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
JP2001172261A (ja) * 1999-12-20 2001-06-26 Mitsubishi Chemicals Corp ピラゾールカルボン酸アミド類、およびこれを有効成分とする殺虫、殺ダニ剤
BRPI0117360B8 (pt) 2000-02-15 2021-07-06 Upjohn Co inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
US6638926B2 (en) * 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1384714A1 (en) * 2001-04-06 2004-01-28 Nihon Nohyaku Co., Ltd. Pyrazolecarboxamide derivative, intermediate therefor, and pest control agent containing the same as active ingredient
JP2002363164A (ja) * 2001-04-06 2002-12-18 Mitsubishi Chemicals Corp ピラゾールカルボキサミド類、その中間体およびこれを有効成分とする有害生物防除剤
JP4575667B2 (ja) 2002-03-08 2010-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬として有用な大環状化合物
PL401638A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
CN101189228A (zh) * 2005-04-08 2008-05-28 辉瑞产品有限公司 用作i型甘氨酸转运抑制剂的二环[3.1.0]杂芳酰胺
CA2609394A1 (en) * 2005-05-23 2006-11-30 Masaki Takagi Pyrazole compound and therapeutic agent for diabetes comprising the same
EP1912636B1 (en) 2005-07-21 2014-06-25 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8552050B2 (en) 2007-08-16 2013-10-08 Beth Israel Deaconess Medical Center Activators of pyruvate kinase M2 and methods of treating disease
JPWO2009028280A1 (ja) * 2007-08-29 2010-11-25 三井化学アグロ株式会社 ピラゾールカルボン酸誘導体及びその製造方法、並びに殺菌剤
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
ES2620634T3 (es) * 2008-10-09 2017-06-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activadores de piruvato quinasa humana
JP5584696B2 (ja) * 2008-11-17 2014-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−１３阻害剤として有用なヘテロアリールジアミド化合物
US20110263647A1 (en) 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
CN102448951B (zh) * 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
EP2427441B1 (en) 2009-05-04 2016-12-14 Agios Pharmaceuticals, Inc. Pkm2 activators for use in the treatment of cancer
US8349832B2 (en) 2009-09-02 2013-01-08 Canthera Therapeutics Compounds and compositions for treating cancer
WO2011069298A1 (en) * 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
CN105482129B (zh) 2010-09-30 2018-07-27 黄奇英 抗癌萃取物及化合物
WO2012056319A1 (en) 2010-10-27 2012-05-03 Dynamix Pharmaceuticals Ltd. Sulfonamides for the modulation of pkm2
EP2651898B1 (en) * 2010-12-17 2015-12-09 Agios Pharmaceuticals, Inc. Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
US9328077B2 (en) 2010-12-21 2016-05-03 Agios Pharmaceuticals, Inc Bicyclic PKM2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
EP2497775A1 (en) 2011-03-11 2012-09-12 Ruprecht-Karls-Universität Heidelberg Ferrocene-based compounds and their use as ROS regulating prodrugs
WO2012160447A1 (en) * 2011-05-25 2012-11-29 Dynamix Pharmaceuticals Ltd. 3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases
WO2013005157A1 (en) 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
DK2909181T3 (da) * 2012-10-16 2017-11-20 Tolero Pharmaceuticals Inc PKM2-modulatorer og fremgangsmåder til anvendelse deraf
CN104822672B (zh) 2012-11-08 2018-08-28 安吉奥斯医药品有限公司 治疗性化合物和组合物以及其作为pkm2调节剂的用途
US9447054B2 (en) 2014-01-15 2016-09-20 Korea Institute Of Radiological & Medical Sciences Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient

Similar Documents

Publication Publication Date Title
JP2020105190A5 (enExample)
JPWO2019150305A5 (enExample)
RU2346702C2 (ru) Применение антител к ctla-4
Mearini et al. A review of penile metastasis.
JP2020143134A5 (enExample)
JP2007530526A5 (enExample)
HRP20201334T1 (hr) Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
JP2021501142A5 (enExample)
JP2025024006A5 (enExample)
RU2014102935A (ru) Кризотиниб для применения в лечении рака
RU2008122471A (ru) Способ лечения аномального роста клеток
RU2014124005A (ru) Комбинация инотузумаба озогамицина и торизела для лечения рака
RU2007110480A (ru) Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы
WO2007143483A2 (en) Combination of pazopanib and lapatinib for treating cancer
RU2013134359A (ru) Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований
JP2023168298A5 (enExample)
RU2010121647A (ru) Полиморфы ингибитора c-met/hgfr
JP2001240542A (ja) 肝細胞性腫瘍処置用薬剤
JP2019529476A5 (enExample)
RU2020113749A (ru) Аналоги таиланстатина
JP2018062523A5 (enExample)
JP2014005265A5 (enExample)
Metwally et al. Ovarian cancer with metastatic inguinal lymphadenopathy: A case series and literature review
JP2024050581A5 (enExample)
JPWO2021059136A5 (enExample)